MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Reparixin L-lysine salt

CAS No. : 266359-93-7

MCE 国际站：Reparixin L-lysine salt

产品活性：Reparixin L-lysine salt是趋化因子受体1/2 (CXCR1/2)活化 的变构抑制剂。

研究领域：GPCR/G Protein  |  Immunology/Inflammation

作用靶点：CXCR

In Vitro: Reparixin is a potent functional inhibitor of CXCL8-induced biological activities on human PMNs with a marked selectivity (around 400-fold) for CXCR1, as shown in specific experiments on CXCR1/L1.2 and CXCR2/L1.2 transfected cells and on human PMNs. The efficacy of Reparixin is significantly lower in L1.2 cells expressing Ile43Val CXCR1 mutant (IC₅₀ values of 5.6 nM and 80 nM for CXCR1 wt and CXCR1 Ile43Val, respectively). Reparixin is a non-competitive allosteric inhibitor of IL-8 receptors with a 400-fold higher efficacy in inhibiting CXCR1 activity than CXCR2.

In Vivo: The pharmacokinetics and metabolism of Reparixin are investigated in rats and dogs after intravenous administration of [¹⁴C]-Reparixin L-lysine salt. Plasma protein binding of Reparixin is >99% in the laboratory animals and humans up to 50 µg/mL, but lower at higher concentrations. Although radioactivity is rapidly distributed into rat tissues, V_ss is low (about 0.15 L/kg) in both rat and dog. Nevertheless, Reparixin is more rapidly eliminated in rats (t_1/2~0.5 h) than in dogs (t_1/2~10 h).

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Small Molecule Immuno-Oncology Compound Library  |  Drug Repurposing Compound Library  |  Endocrinology Compound Library  |  Orally Active Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Rare Diseases Drug Library  |  Chemokine Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Highly Selective Inhibitors Library  |  Nicotinamide N-oxide  |  SX-517  |  AMG 487 (S-enantiomer)  |  TC14012  |  CTCE-9908  |  CXCR2 antagonist 3  |  Kynurenic acid-d₅  |  (R,R)-CXCR2-IN-2  |  IT1t dihydrochloride  |  NUCC-390  |  Ac-Pro-Gly-Pro-OH  |  Vimnerixin  |  NBI-74330  |  CXCR4 antagonist 9  |  Quetmolimab  |  PS372424 hydrochloride  |  SCH 546738  |  vMIP-II (1-21)  |  CXCR2-IN-1  |  Mavorixafor  |  VUF11207 fumarate  |  NoxaBH3  |  Kynurenic acid  |  CXCR4 antagonist 2  |  Balixafortide  |  Plerixafor octahydrochloride  |  Ladarixin

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。